Immix Average Receivables from 2010 to 2025
| IMMX Stock | USD 1.83 0.01 0.55% |
Average Receivables | First Reported 2010-12-31 | Previous Quarter 527.5 K | Current Value 290.7 K | Quarterly Volatility 143.8 K |
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 414.7 K or Depreciation And Amortization of 6.6 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 4.93 or Book Value Per Share of 0.27. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
Immix | Average Receivables |
Latest Immix Biopharma's Average Receivables Growth Pattern
Below is the plot of the Average Receivables of Immix Biopharma over the last few years. It is Immix Biopharma's Average Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Average Receivables | 10 Years Trend |
|
Average Receivables |
| Timeline |
Immix Average Receivables Regression Statistics
| Arithmetic Mean | 202,098 | |
| Geometric Mean | 174,834 | |
| Coefficient Of Variation | 71.15 | |
| Mean Deviation | 99,750 | |
| Median | 140,714 | |
| Standard Deviation | 143,797 | |
| Sample Variance | 20.7B | |
| Range | 445.4K | |
| R-Value | 0.59 | |
| Mean Square Error | 14.4B | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | 17,908 | |
| Total Sum of Squares | 310.2B |
Immix Average Receivables History
About Immix Biopharma Financial Statements
Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Average Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Average Receivables | 527.5 K | 290.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.